DENVER, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative neuromonitoring (“IONM”) and remote neurology services, announced today that it held its annual general meeting of shareholders on December 28, 2022 (the “Meeting”) and that all matters submitted to the shareholders of the Company for approval as set out in the Company’s definitive proxy statement dated December 2, 2022 (the “Proxy Statement”), were approved by the requisite majority of votes cast at the Meeting, including:
For further details regarding the matters approved at the Meeting, please see a copy of the Proxy Statement, which is available on the Company’s profile at www.sec.gov.
About Assure Holdings
Assure Holdings Corp. is a best-in-class provider of outsourced intraoperative neuromonitoring and remote neurology services. The Company delivers a turnkey suite of clinical and operational services to support surgeons and medical facilities during invasive procedures that place the nervous system at risk including neurosurgery, spine, cardiovascular, orthopedic and ear, nose and throat surgeries. Assure employs highly trained technologists that provide a direct point of contact in the operating room. Physicians employed through Assure subsidiaries simultaneously monitor the functional integrity of patients’ neural structures throughout the procedure communicating in real-time with the surgeon and technologist. Accredited by The Joint Commission, Assure’s mission is to provide exceptional surgical care and a positive patient experience. For more information, visit the company’s website at www.assureneuromonitoring.com.
Contact
Scott Kozak, Investor and Media Relations
Assure Holdings Corp.
1-720-617-2526
This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$0.05 |
| Daily Volume: | 0 |
| Market Cap: | US$150K |
February 12, 2024 August 15, 2023 August 03, 2023 June 26, 2023 | |

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load